Company intelligence / Profile preview
35Pharma
Montreal, Quebec, Canada35pharma.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
35Pharma has initiated Phase 1 clinical trials for its two lead assets. HS235 is being evaluated in overweight and obese healthy subjects, while HS135 is advancing toward proof-of-concept studies in pulmonary hypertension and heart failure with preserved ejection fraction. Both assets are designed to selectively inhibit pathological Activin and GDF signaling implicated in cardiometabolic and pulmonary diseases. No efficacy data from these trials have been published yet.
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Protein drugsAntibody fusion proteinsLigand traps (biologics targeting TGF-beta superfamily)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No specific major pharma partnerships disclosed publicly as of May 2025; company notes experience with pharma partnerships among leadership but no named deals.
Beyond the preview
Go deeper on 35Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 35Pharma.